SVRA Savara Inc.
Savara Inc. (SVRA) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.0% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Savara Inc.
Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.
Sector
Healthcare
Industry
Drug Manufacturers/Other